Family of drugs used for treating muscular dystrophy could improve brain tumor treatment

A drug from the same family licensed for use in patients with Duchenne muscular dystrophy and blood cancer could transform the treatment of meningioma—the most common form of primary brain tumor in adults. Scientists at the Brain Tumor Research Center of Excellence at the University of Plymouth carried out the research using patient samples in the laboratory, and the results have been published in the journal Cell Death & Disease.